OUR INITIAL INDICATIONS
From proven drugs to brain-targeted medicines.
Braindoot’s pipeline is guided by our mission to transform outcomes in brain and CNS disease treatments. At present, our focus is on optimizing proprietary platforms and refining the development loop to efficiently identify high‑potential drug candidates with an improved success rate for integration into the pipeline.
BDL-001 / LEAD INDICATION
Brain Metastases
An existing, FDA-approved CDK4/6 inhibitor — proven in HR+/HER2- breast cancer — re-armed with BLiS™ to finally cross the blood-brain barrier.
WHY
No approved drug specifically overcomes the BBB to deliver CDK4/6 activity into the brain.
The payload is an existing CDK4/6 inhibitor that’s already clinically validated; efficacy isn’t in question, brain delivery is.
Efficacy isn’t in question — delivery is. Palbociclib already works systemically; no approved drug overcomes the BBB to bring CDK4/6 activity into the brain.
De-risked pharmacology. Building on a clinically validated, FDA-approved molecule shortens the path to proof of concept.
168K+
US CASES / YEAR
$4.0B
2025 MARKET SIZE
16.9 mo
MEDIAN SURVIVAL
BDL-006 / SECOND INDICATION
Refractory Glioblastoma
A novel compound targeting SP-1, based on unpublished preclinical data showing significant anti-tumor efficacy in GBM models — a first-in-class CNS target with no competing programs today.
Target validity isn’t the obstacle. Most GBM drugs fail from lack of CNS exposure, compounded by tumor stemness — not from a weak target.
Real biological activity, early. Preclinical and translational data already support SP-1 as a clinically relevant target.
15K+
US CASES / YEAR
$3.5B
2025 MARKET SIZE
6.8 mo
MEDIAN SURVIVAL
BDL-001 and BDL-006 are designed to validate the platform.
Once validated, the same DRiS prediction, BLiS™ delivery, and LTiS system extend to traumatic brain injury and additional CNS indications.
TBI and the broader CNS pipeline follow the same engine.
BDL-001 and BDL-006 exist to prove the platform. Once validated, the same ML prediction, BLiS™ delivery, and humanized BBB system extend to traumatic brain injury and additional CNS indications — without starting from scratch each time.